Fingerprint
Dive into the research topics of 'Phase I study of alvocidib followed by 7+3 (cytarabine + daunorubicin) in newly diagnosed acute myeloid leukemia'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase I study of alvocidib followed by 7+3 (cytarabine + daunorubicin) in newly diagnosed acute myeloid leukemia
Joshua F. Zeidner, Daniel J. Lee, Mark Frattini, Gil D. Fine, Judy Costas, Kathryn Kolibaba, Stephen P. Anthony, David Bearss, B. Douglas Smith
Research output: Contribution to journal › Article › peer-review
1
Scopus
citations